Opentrons Secures $40M Series E to Automate the AI Wet-Lab Bottleneck

LONG ISLAND CITY, NY – October 29, 2026 – Artificial intelligence has fundamentally rewritten the timeline for biological discovery. Generative models can now predict protein structures, identify novel drug targets, and design complex therapeutics in mere minutes. Yet, this computational miracle routinely crashes into a very physical wall: the traditional wet lab. While algorithms can generate thousands of viable hypotheses overnight, the physical execution of testing these theories remains a stubbornly manual, error-prone, and time-intensive process.

To bridge this widening divide between computational speed and physical reality, Opentrons Labworks Inc. today announced a $40 million Series E financing round. Led by healthcare investment firm Avego, with participation from BroadOak Capital Partners, the capital injection is a targeted strategic move to scale the company’s robotics, software, and data infrastructure.

The investment highlights a critical shift in the life sciences sector. As the initial hype cycle surrounding generative AI in biotech begins to mature, industry leaders and investors are realizing that the true bottleneck to next-generation drug discovery is no longer computational power, but physical execution. By standardizing the hardware layer of biological experimentation, the New York-based enterprise is positioning itself as the indispensable bridge between digital AI models and physical laboratory results.

The Wet-Lab Bottleneck: AI's Physical Reality Check

The core problem plaguing modern biotechnology is one of asynchronous innovation. Frontier AI models are advancing at an exponential rate, but the physical laboratories required to validate their outputs are largely operating on decades-old paradigms. Scientists are increasingly forced to act as high-priced pipetting machines, spending countless hours manually transferring liquids to test the predictions generated by their algorithms.

This manual execution not only slows down the pace of discovery but also introduces human error, compromising the reproducibility of the data—a fatal flaw when feeding results back into data-hungry machine learning models.

"Millions of scientists spend much of their day on manual work a robot can do. Giving that time back to discovery is the biggest opportunity in science," said James Atwood, PhD, CEO of Opentrons. "We made lab automation accessible for any lab, and our systems are built for AI to run experiments directly. That is why autonomous science is standardizing on Opentrons."

The company’s flagship Flex platform is designed specifically to close this gap. Rather than functioning as a simple, pre-programmed liquid handler, the system is engineered to operate in a continuous learning loop. Experiments can be designed by an AI agent, executed by the robotic hardware, and the resulting structured data is immediately fed back into the computational model to refine the next iteration. This closed-loop system is the holy grail of modern pharmacokinetics, enabling a genuinely autonomous scientific method.

Disrupting the Giants: The Open-Source Advantage

Capturing 90 percent of the top 20 global pharmaceutical companies and all top-20 U.S. research universities is a staggering achievement for a company that originated in the Y Combinator accelerator just over a decade ago. The robotics manufacturer achieved this market penetration by fundamentally ignoring the established playbook of legacy lab automation giants.

Historically, the laboratory automation market has been dominated by entrenched players like Tecan, Hamilton, and Beckman Coulter. These industry stalwarts built their empires on massive, proprietary, and highly expensive systems tailored for massive-scale, static operations. While powerful, these legacy machines often require specialized technicians to program and are notoriously difficult to integrate with third-party software or modern cloud infrastructures.

Opentrons took the exact opposite approach. By leveraging open-source architecture and an API-first design philosophy, the firm democratized access to lab automation. Their robots are significantly more affordable, allowing them to be deployed not just in massive centralized facilities, but directly on the benches of individual academic researchers and agile biotech startups.

More importantly, the API-driven nature of the platform makes it inherently "AI-native." Software developers and computational biologists can write custom code to command the robots directly from their own tech stacks, bypassing clunky proprietary interfaces. With over 11,000 robots currently deployed across 80 countries, this strategy has effectively crowdsourced a massive library of open-source protocols, creating a powerful network effect that legacy competitors are struggling to replicate.

The "Picks and Shovels" Play in a Shifting VC Landscape

The $40 million Series E round arrives during a period of recalibration in the venture capital markets. Following the explosive funding environment of the early 2020s—which saw the company achieve a $1.8 billion valuation following a $200 million Series C in 2021—investors have become markedly more disciplined.

In this tighter economic climate, capital is rotating away from highly speculative AI drug developers, many of which are years away from clinical trials, and toward the foundational infrastructure providers. This is a classic "picks and shovels" investment strategy. Regardless of which AI biotech startup ultimately discovers the next blockbuster drug, they will all require the physical hardware to test their hypotheses.

"Every AI-driven discovery still has to be tested in a real lab," noted James Flexner, Managing Partner at Avego. "Drug developers and AI companies alike are moving experimental work forward toward automated workflows that generate usable data. We see a significant opportunity for autonomous science to converge around Opentrons’ platform."

The involvement of Avego, a firm known for its hands-on operational expertise in healthcare, alongside BroadOak Capital Partners—which recently added over $200 million of permanent capital to its own platform—signals strong institutional confidence in the hardware manufacturer's path to profitability. While the $40 million raise is smaller than the company's previous mega-rounds, it reflects a targeted, strategic infusion of capital designed to fund specific execution goals rather than simply inflate valuations. It also mirrors a broader industry trend, with competitors like Automata and Multiply Labs recently securing $45 million and $75 million respectively, underscoring the intense market demand for automated, AI-ready laboratories.

Building the Autonomous Execution Layer

Looking ahead, the strategic imperative for the firm is to solidify its position as the de facto execution layer for biological research. The Series E funding will be channeled heavily into enhancing AI-driven experimental execution, expanding the software's capabilities, and deepening integrations into the broader lab automation ecosystem.

The company has already proven its ability to scale rapidly under pressure. During the height of the COVID-19 pandemic, it partnered with New York State to establish the Pandemic Response Lab, demonstrating that its affordable robotics could handle massive, high-throughput clinical demands. Now, operating with an estimated annual revenue of $45 million and a leaner, optimized workforce, the organization is applying that same scalable architecture to the complexities of generative biology.

Recent strategic moves, including partnerships with tech behemoths like NVIDIA to develop physical-AI tools, indicate a future where the distinction between the software designing the experiment and the hardware executing it becomes entirely seamless. As the life sciences industry continues its rapid digital transformation, the companies that control the physical execution of AI-generated ideas will command immense strategic value, dictating the pace of innovation for the entire sector.